Biomedical Engineering Reference
In-Depth Information
27. Swantek JL, Cobb MH, Geppert TD. Jun N-terminal kinase
=
stress-activated
protein kinase (JNK
=
SAPK) is required for hypopolysaccharides stimulation
of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhi-
bit TNF-alpha translation by blocking JNK
=
SAPK. Mol Cell Biol 1997;
17:6274-6282.
28. Caelles C, Gonzalez-Sancho JM, Munoz A. Nuclear hormone receptor antag-
onism with AP-1 by inhibition of the JNK pathway. Genes Dev 1997;
11:3351-3364.
29. Rider LG, Hirasawa N, Santini F, Beaven MA. Activation of the mitogen-
activated protein kinase cascade is suppressed by low concentrations of dexa-
methasone in mast cells. J Immunol 1996; 157:2374-2380.
30. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR. Dexametha-
sone causes sustained expression of mitogen-activated protein kinase (MAPK)
phosphatase 1 and phosphatase-mediated inhibition of MAPKp38. Mol Cell
Biol 2002; 22:7802-7811.
31. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. Gluco-
corticoids inhibit MAP kinase via increased expression and decreased degra-
dation of MKP-1. EMBO J 2001; 20:7108-7116.
32. Imasato A, Desbois-Mouthon C, Han J, Kai H, Cato AC, Akira S, et al.
Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phospha-
tase-1 enhances nontypeable Haemophilus influenzae-induced expression of
toll-like receptor 2. J Biol Chem 2002; 277:47, 444-447, 450.
33. Engelbrecht Y, de Wet H, Horsch K, Langeveldt CR, Hough FS, Hulley PA.
Glucocorticoids induce rapid up-regulation of mitogen-activated protein
kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated
kinase and impair proliferation in human and mouse osteoblast cell lines.
Endocrinology 2003; 144:412-422.
34. Rogatsky I, Logan SK, Garabedian MJ. Antagonism of glucocorticoid recep-
tor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad
Sci USA 1998; 95:2050-2055.
35. Clark AR. MAP kinase phosphatase 1: a novel mediator of biological effects
of glucocorticoids? J Endocrinol 2003; 178:5-12.
36. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects
of glucocorticoids. Pharmacol Ther 2002; 96:23-43.
37. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R,
et al. DNA binding of the glucocorticoid receptor is not essential for survival.
Cell 1998; 93:531-541.
38. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone
deacetylase 2 inhibits interleukin-1 beta-induced histone H4 acetylation on
lysines 8 and 12. Mol Cell Biol 2000; 20:6891-6903.
39. Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ, et al. Expression
and activity of histone deacetylases in human asthmatic airways. Am J Respir
Crit Care Med 2002; 166:392-396.
40. O'Riordan TG. Inhaled corticosteroids in chronic obstructive pulmonary
disease: new trials and old practices. J Aerosol Med 2003; 16:1-8.
41. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postrna DS, Pride NB,
et al. Long-term treatment with inhaled budesonide in persons with mild
